Celldex is dropping barzolvolimab in eczema after a Phase 2 failure, though it still plans to file the drug in chronic hives next year. https://t.co/ygG2Fu2IaT
Merck's ADC sac-TMT scored another Phase 3 win, this time in gastric cancer, as it looks to offset Keytruda's looming patent cliff. https://t.co/7b4XoZYdA5
A congressional biotech panel is closing out with a warning on China deal flow, though its leader says "we hope that we're wrong." https://t.co/WnTH7TTtMU
In this week's Peer Review: Teva is on the hunt for a new R&D head, and Summit's FDA rejection came after its commercial chief's exit. https://t.co/MmOWB7YYhk
After a rocky third quarter, Novartis touted a mid-stage eczema win and said it's working to restart trials of its autoimmune CAR-T. https://t.co/SjDUm5fFnC
The FDA approved Regeneron's Livsayis for myasthenia gravis, marking its entry into neurology and the second new drug for the disease in a week. https://t.co/VWQaOswKTz
Sanofi is considering a deal to buy Insmed, according to Bloomberg, in what would be one of the biggest biopharma takeovers in years. https://t.co/WpodsZ8sub
AbbVie will pay Disco $40M upfront in a deal worth up to $2.54B to find solid tumor targets for its ADC and T cell engager programs. https://t.co/LwRvAc7F2w
An @endpts exclusive: Inside Heidi Overton's failed FDA nomination, and the new, powerful White House-MAHA alliance that tanked it.
https://t.co/2pDm2yycFT
The White House pulled Heidi Overton's nomination to lead the FDA, leaving only weeks to find a replacement before Democrats take the Senate. https://t.co/runLgxP3ll
Pfizer will pay $330M upfront to Chinese biotech Starna Therapeutics for in vivo CAR-T assets, marking its entry into the space. https://t.co/YzziCw3BpE